UBS Sticks to Their Buy Rating for GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh (GQG)
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Patel CFA covers the Financial sector, focusing on stocks such as GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh, Insignia Financial Ltd, and Magellan Financial Group Ltd. According to TipRanks, Patel CFA has an average return of 13.4% and a 68.09% success rate on recommended stocks.
GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh has an analyst consensus of Strong Buy, with a price target consensus of A$2.95, implying a 32.29% upside from current levels. In a report released on June 22, RBC Capital also initiated coverage with a Buy rating on the stock with a A$2.90 price target.
GQG market cap is currently A$6.65B and has a P/E ratio of 10.07.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GQG in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
11 minutes ago
- San Francisco Chronicle
Crescent Capital BDC: Q2 Earnings Snapshot
LOS ANGELES (AP) — LOS ANGELES (AP) — Crescent Capital BDC, Inc. (CCAP) on Wednesday reported second-quarter earnings of $15 million. On a per-share basis, the Los Angeles-based company said it had profit of 41 cents. Earnings, adjusted for investment costs, came to 46 cents per share. The results met Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was also for earnings of 46 cents per share. The company posted revenue of $43 million in the period. _____
Business Wire
11 minutes ago
- Business Wire
Adagio Medical Reports Second Quarter 2025 Results
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ('Adagio' or 'the Company'), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2025. Recent Business Highlights: Surpassed 85% enrollment in the FULCRUM-VT pivotal study of the Company's vCLAS™ Cryoablation System. The study, which seeks to enroll 206 patients with either ischemic or non-ischemic drug-refractory, recurrent, sustained monomorphic ventricular tachycardia ('VT') at 20 U.S. and Canadian centers, is on track for completion of patient enrollment in the second half of 2025 First-in-human results from the PARALELL study, which evaluated the safety and effectiveness of Adagio's Pulsed Field Cryoablation ('PFCA'), a novel, dual-energy cardiac ablation modality combining Pulsed Field Ablation (PFA) with Adagio's proprietary Ultra-Low Temperature Cryoablation ('ULTC'), were published in the Journal of Cardiovascular Electrophysiology Reduced cash burn quarter-over-quarter as a result of the Company's corporate prioritization initiative, which streamlined operations and focused resources on highest-value programs 'In the second quarter we saw continued strong momentum in the enrollment of our FULCRUM-VT study, which we believe validates the market need for our purpose-built technology and brings us one step closer to offering our proprietary ULTC solutions to patients in the United States who suffer from ventricular tachycardia,' said Todd Usen, Chief Executive Officer of Adagio. 'The team also made meaningful progress in advancing our pipeline through the continued development of our next-generation product, which is designed to improve usability for physicians while further enhancing the capabilities of our differentiated ULTC platform.' Second Quarter 2025 Financial Results Cost of revenue was $0.3 million for the three months ended June 30, 2025, compared to $0.7 million for the three months ended June 30, 2024. Research and development expenses were $2.0 million for the three months ended June 30, 2025 compared to $2.9 million for the three months ended June 30, 2024 Selling, general and administrative expenses were $2.4 million for the three months ended June 30, 2025, compared to $3.4 million for the three months ended June 30, 2024. Net loss for the three months ended June 30, 2025, was $3.9 million, or $(0.26) per share (Basic), compared to a net loss of $5.7 million, or $(7.35) per share (Basic), for the three months ended June 30, 2024. Reported cash and cash equivalents of $8.2 million as of June 30, 2025. About Adagio Medical Holdings, Inc. Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular tachycardia (VT) with its purpose-built vCLAS™ Cryoablation System, which is CE Marked and is currently under evaluation in the Company's FULCRUM-VT U.S. IDE Pivotal Study. About FULCRUM VT FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm study, enrolling 206 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory VT in accordance with current treatment guidelines. The results of the study will be used to apply for FDA premarket approval (PMA) for Adagio's vCLAS™ Cryoablation System, potentially leading to the broadest industry indication for purely endocardial ablation of scar-mediated VT. Adagio's vCLAS™ Cryoablation System is commercially available for the treatment of monomorphic ventricular tachycardia in Europe and select other geographies but is limited to investigational use in the United States. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'projects,' 'plans,' and 'future' or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning: the potential of Adagio's vCLAS™ Cryoablation System; Adagio's research, development and regulatory plans for its product candidates, including the timing of initiating additional trials and reporting data from its trials; the ability of Adagio to bring its proprietary ULTC solutions to patients in the United States who suffer from VT and their ability to improve usability for physicians; the potential for its product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies; and its current cash resources and the impacts of its corporate prioritization initiative and realignment of resources. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Adagio's business are described in detail in Adagio's Securities and Exchange Commission ('SEC') filings, including in its Annual Report on Form 10-K for the full-year ended December 31, 2024, which is available on the SEC's website at Additional information will be made available in other filings that Adagio makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Adagio disclaims any obligation to update these statements except as may be required by law.
Business Wire
11 minutes ago
- Business Wire
Kimball Electronics Reports Q4 Results With Solid Finish to the Fiscal Year; Company Provides Guidance for Fiscal 2026
JASPER, Ind.--(BUSINESS WIRE)--Kimball Electronics, Inc. (Nasdaq: KE) today announced financial results for the fourth quarter and fiscal year ended June 30, 2025. Kimball Electronics reports Q4 results with solid finish to the fiscal year; company provides guidance for fiscal 2026. Share Three Months Ended Fiscal Year Ended June 30, June 30, (Amounts in Thousands, except EPS) 2025 2024 2025 2024 Net Sales $ 380,472 $ 430,158 $ 1,486,727 $ 1,714,510 Operating Income $ 16,474 $ 19,608 $ 45,535 $ 49,277 Adjusted Operating Income (non-GAAP) (1) $ 19,638 $ 22,694 $ 61,267 $ 81,496 Operating Income % 4.3 % 4.6 % 3.1 % 2.9 % Adjusted Operating Income (non-GAAP) % 5.2 % 5.3 % 4.1 % 4.8 % Net Income $ 6,581 $ 7,543 $ 16,984 $ 20,511 Adjusted Net Income (non-GAAP) (1) $ 8,438 $ 9,688 $ 28,156 $ 41,295 Diluted EPS $ 0.26 $ 0.30 $ 0.68 $ 0.81 Adjusted Diluted EPS (non-GAAP) (1) $ 0.34 $ 0.38 $ 1.12 $ 1.64 Expand (1) Beginning in the first quarter of fiscal year 2025, adjusted results exclude stock compensation expense. Prior reported periods have been revised accordingly. A reconciliation of GAAP and non-GAAP financial measures is included below. Expand Commenting on today's announcement, Richard D. Phillips, Chief Executive Officer, stated, 'I'm encouraged by the results for the fourth quarter and solid finish to the fiscal year. Q4 came in better than expected, as sales increased sequentially, margins improved, and working capital management drove our sixth consecutive quarter of positive cash flow which was used to pay down debt. Our balance sheet is now in a position of competitive strength with ample liquidity to weather an unpredictable environment, while providing dry powder for opportunistic investments.' Mr. Phillips continued, 'In total, fiscal 2025 was a year of 'controlling what we could control'. I'm proud of our team as we made significant progress positioning the Company for a return to profitable growth with a record number of wins for future business, adjusting the cost structure and aligning the portfolio to demand trends, and intensifying our focus as a medical CMO. We expect fiscal 2026 to be another step forward in the journey which will unfold over time.' The Company ended the fourth quarter of fiscal 2025 with cash and cash equivalents of $88.8 million and borrowing capacity of $291.7 million. The Company invested $3.0 million to repurchase 162,000 shares of common stock. Fiscal Year 2025 Highlights Net sales totaled $1,486.7 million, the third highest annual revenue total for the Company Operating income of $45.5 million, or 3.1% of net sales; adjusted operating income of $61.3 million, or 4.1% of net sales Inventory reduced $64.6 million, or 19%, in the fiscal year Debt paid down by $147.3 million, or 50%, year-over-year; the lowest level of debt in 3 years Cash generated from operating activities of $183.9 million, a record result for annual cash flow Invested $12.0 million to repurchase 653,000 shares of common stock Net Sales by Vertical Market for Q4 and Full Year Fiscal 2025: * As a percent of Total Net Sales (1) Sales from our Automation, Test, and Measurement business (AT&M), which was divested effective July 31, 2024, were previously included in the Industrial vertical ─ Automotive includes electronic power steering, body controls, automated driver assist systems, and electronic braking systems ─ Medical includes sleep therapy and respiratory care, image guided therapy, in vitro diagnostics, drug delivery, AED, and patient monitoring ─ Industrial includes climate controls, automation controls, and public safety Expand 'Fiscal 2026 will be a year of transition. We expect modest top line growth in our medical and industrial businesses, but it will be offset by a decline in automotive, with a full year impact from the loss of the braking program in Reynosa. Margins are estimated to be in line with FY25, but it's important to note that when top line growth returns, enhancements to our cost structure should support margin improvement. Capital expenditures will be heavily weighted toward our new facility in Indianapolis, with the balance supporting growth, automation, and maintenance.' Jana T. Croom Chief Financial Officer Fiscal Year 2026 Guidance Net sales of $1,350 - $1,450 million, a 2% to 9% decrease compared to fiscal 2025 Adjusted operating income of 4.0% - 4.25% of net sales, compared to 4.1% of net sales in fiscal 2025 Capital expenditures of $50 - $60 million Forward-Looking Statements Certain statements contained within this release are considered forward-looking, including our guidance, under the Private Securities Litigation Reform Act of 1995. The statements may be identified by the use of words such as 'expect,' 'should,' 'goal,' 'predict,' 'will,' 'future,' 'optimistic,' 'confident,' and 'believe.' Undue reliance should not be placed on these forward-looking statements. These statements are based on current expectations of future events and thus are inherently subject to uncertainty. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. These forward-looking statements are subject to risks and uncertainties including, without limitation, global economic conditions, geopolitical environment and conflicts such as the war in Ukraine, global health emergencies, availability or cost of raw materials and components, tariffs and other trade barriers, foreign exchange rate fluctuations, and our ability to convert new business opportunities into customers and revenue. Additional cautionary statements regarding other risk factors that could have an effect on the future performance of the company are contained in its Annual Report on Form 10-K for the year ended June 30, 2024. Non-GAAP Financial Measures This press release contains non-GAAP financial measures. The non-GAAP financial measures contained herein include constant currency growth, net sales excluding Automation, Test & Measurement, adjusted selling and administrative expenses, adjusted operating income, adjusted net income, adjusted diluted EPS, and ROIC. Reconciliations of the reported GAAP numbers to these non-GAAP financial measures are included in the Reconciliation of Non-GAAP Financial Measures section below. Management believes these measures are useful and allow investors to meaningfully trend, analyze, and benchmark the performance of the company's core operations. The company's non-GAAP financial measures are not necessarily comparable to non-GAAP information used by other companies. About Kimball Electronics, Inc. Kimball Electronics is a global, multifaceted manufacturer offering Electronics Manufacturing Services (EMS) and Contract Manufacturing Organization (CMO) solutions to customers around the world. From our operations in the United States, China, Mexico, Poland, Romania, and Thailand, our teams are proud to provide manufacturing services for a variety of industries. Recognized for a reputation of excellence, we are committed to a high-performance culture that values quality, reliability, value, speed, and ethical behavior. Kimball Electronics, Inc. (Nasdaq: KE) is headquartered in Jasper, Indiana. To learn more about Kimball Electronics, visit Lasting relationships. Global success. Financial highlights for the fourth quarter and fiscal year ended June 30, 2025 are as follows: Condensed Consolidated Statements of Income (Unaudited) Three Months Ended (Amounts in Thousands, except Per Share Data) June 30, 2025 June 30, 2024 Net Sales $ 380,472 100.0 % $ 430,158 100.0 % Cost of Sales 349,991 92.0 % 393,420 91.5 % Gross Profit 30,481 8.0 % 36,738 8.5 % Selling and Administrative Expenses 13,163 3.5 % 15,890 3.6 % Restructuring Expense 1,971 0.5 % 764 0.2 % Asset Impairment (Gain on Disposal) (1,127 ) (0.3 )% 476 0.1 % Operating Income 16,474 4.3 % 19,608 4.6 % Interest Income 196 0.1 % 155 — % Interest Expense (2,776 ) (0.7 )% (5,380 ) (1.3 )% Non-Operating Income (Expense), net (1,177 ) (0.4 )% (918 ) (0.2 )% Other Income (Expense), net (3,757 ) (1.0 )% (6,143 ) (1.5 )% Income Before Taxes on Income 12,717 3.3 % 13,465 3.1 % Provision for Income Taxes 6,136 1.6 % 5,922 1.3 % Net Income $ 6,581 1.7 % $ 7,543 1.8 % Earnings Per Share of Common Stock: Basic $ 0.27 $ 0.30 Diluted $ 0.26 $ 0.30 Average Number of Shares Outstanding: Basic 24,552 25,064 Diluted 24,840 25,246 Expand (Unaudited) Fiscal Year Ended (Amounts in Thousands, except Per Share Data) June 30, 2025 June 30, 2024 Net Sales $ 1,486,727 100.0 % $ 1,714,510 100.0 % Cost of Sales 1,382,323 93.0 % 1,574,253 91.8 % Gross Profit 104,404 7.0 % 140,257 8.2 % Selling and Administrative Expenses 50,270 3.4 % 66,626 4.0 % Other General Expense (Income) — — % (892 ) (0.1 )% Restructuring Expense 10,990 0.7 % 2,386 0.1 % Goodwill Impairment — — % 5,820 0.3 % Asset Impairment (Gain on Disposal) (2,391 ) (0.2 )% 17,040 1.0 % Operating Income 45,535 3.1 % 49,277 2.9 % Interest Income 771 0.1 % 638 — % Interest Expense (14,745 ) (1.0 )% (22,839 ) (1.3 )% Non-Operating Income (Expense), net (5,332 ) (0.4 )% (1,877 ) — % Other Income (Expense), net (19,306 ) (1.3 )% (24,078 ) (1.4 )% Income Before Taxes on Income 26,229 1.8 % 25,199 1.5 % Provision for Income Taxes 9,245 0.7 % 4,688 0.3 % Net Income $ 16,984 1.1 % $ 20,511 1.2 % Earnings Per Share of Common Stock: Basic $ 0.68 $ 0.82 Diluted $ 0.68 $ 0.81 Average Number of Shares Outstanding: Basic 24,782 25,079 Diluted 25,017 25,278 Expand Condensed Consolidated Statements of Cash Flows Fiscal Year Ended (Unaudited) June 30, (Amounts in Thousands) 2025 2024 Net Cash Flow provided by Operating Activities $ 183,937 $ 73,217 Net Cash Flow used for Investing Activities (14,700 ) (46,521 ) Net Cash Flow (used for) provided by Financing Activities (160,874 ) 8,974 Effect of Exchange Rate Change on Cash, Cash Equivalents, and Restricted Cash 2,325 (755 ) Net Increase in Cash, Cash Equivalents, and Restricted Cash 10,688 34,915 Cash, Cash Equivalents, and Restricted Cash at Beginning of Period 78,779 43,864 Cash, Cash Equivalents, and Restricted Cash at End of Period $ 89,467 $ 78,779 Expand (Unaudited) Condensed Consolidated Balance Sheets June 30, 2025 June 30, 2024 (Amounts in Thousands) ASSETS Cash and cash equivalents $ 88,781 $ 77,965 Receivables, net 222,623 282,336 Contract assets 71,812 76,320 Inventories 273,500 338,116 Prepaid expenses and other current assets 36,027 44,682 Assets held for sale 6,861 27,587 Property and Equipment, net 264,804 269,659 Goodwill 6,191 6,191 Other Intangible Assets, net 2,427 2,994 Other Assets, net 104,286 82,069 Total Assets $ 1,077,312 $ 1,207,919 LIABILITIES AND SHARE OWNERS ' EQUITY Current portion of long-term debt $ 17,400 $ 59,837 Accounts payable 218,805 213,551 Advances from customers 35,867 30,151 Accrued expenses 46,489 63,189 Liabilities held for sale — 8,594 Long-term debt, less current portion 129,650 235,000 Long-term income taxes payable — 3,255 Other long-term liabilities 59,217 53,881 Share Owners' Equity 569,884 540,461 Total Liabilities and Share Owners' Equity $ 1,077,312 $ 1,207,919 Expand Other Financial Metrics (Unaudited) (Amounts in Millions, except CCD) At or For the Three Months Ended June 30, March 31, June 30, 2025 2025 2024 Depreciation and Amortization $ 9.6 $ 9.2 $ 9.5 Cash Conversion Days (CCD) (1) 85 99 100 Open Orders (2) $ 702 $ 642 $ 714 Expand (1) Cash Conversion Days ('CCD') are calculated as the sum of Days Sales Outstanding plus Contract Asset Days plus Production Days Supply on Hand less Accounts Payable Days and less Advances from Customers Days. CCD, or a similar metric, is used in our industry and by our management to measure the efficiency of managing working capital. (2) Open Orders are the aggregate sales price of production pursuant to unfulfilled customer orders. Expand Select Financial Results of Automation, Test and Measurement (Unaudited) (Amounts in Millions) Three Months Ended Fiscal Year Ended June 30, June 30, 2025 2024 2025 2024 Net Sales $ — $ 14.8 $ 2.1 $ 45.7 Operating Income (Loss) (1) $ 1.1 $ 2.0 $ 2.0 $ (22.2 ) Expand (1) Includes gain on sale of $1.1 million for the three months ended June 30, 2025 and $2.4 million for fiscal year 2025 following the close of the sale on July 31, 2024. Includes goodwill impairment of $5.8 million and asset impairment of $17.0 million for the year ended June 30, 2024. Each period also includes allocated corporate overhead expenses. Expand Reconciliation of Non-GAAP Financial Measures (Unaudited, Amounts in Thousands, except Per Share Data) Three Months Ended Fiscal Year Ended June 30, June 30, 2025 2024 2025 2024 Net Sales Growth (vs. same period in prior year) (12 )% (13 )% (13 )% (6 )% Foreign Currency Exchange Impact 1 % — % 1 % — % Constant Currency Growth (13 )% (13 )% (14 )% (6 )% Selling and Administrative Expenses, as reported $ 13,163 $ 15,890 $ 50,270 $ 66,626 Stock Compensation Expense (1,991 ) (1,750 ) (6,519 ) (7,185 ) SERP (329 ) (96 ) (614 ) (680 ) Adjusted Selling and Administrative Expenses $ 10,843 $ 14,044 $ 43,137 $ 58,761 Operating Income, as reported $ 16,474 $ 19,608 $ 45,535 $ 49,277 Stock Compensation Expense 1,991 1,750 6,519 7,185 SERP 329 96 614 680 Legal Settlements (Recovery) — — — (892 ) Restructuring Expense 1,971 764 10,990 2,386 Goodwill Impairment — — — 5,820 Asset Impairment (Gain on Disposal) (1,127 ) 476 (2,391 ) 17,040 Adjusted Operating Income $ 19,638 $ 22,694 $ 61,267 $ 81,496 Net Income, as reported $ 6,581 $ 7,543 $ 16,984 $ 20,511 Stock Compensation Expense, After-Tax 1,510 1,327 4,944 5,449 Legal Settlements (Recovery), After-Tax — — — (676 ) Restructuring Expense, After-Tax 1,474 580 8,314 1,810 Goodwill Impairment, After-Tax — — — 4,414 Asset Impairment (Gain on Disposal), After-Tax (1,127 ) 238 (2,086 ) 9,787 Adjusted Net Income $ 8,438 $ 9,688 $ 28,156 $ 41,295 Diluted Earnings per Share, as reported $ 0.26 $ 0.30 $ 0.68 $ 0.81 Stock Compensation Expense 0.06 0.05 0.19 0.22 Legal Settlements (Recovery) — — — (0.03 ) Restructuring Expense 0.06 0.02 0.33 0.07 Goodwill Impairment — — — 0.18 Asset Impairment (Gain on Disposal) (0.04 ) 0.01 (0.08 ) 0.39 Adjusted Diluted Earnings per Share $ 0.34 $ 0.38 $ 1.12 $ 1.64 Fiscal Year Ended June 30, 2025 2024 Operating Income $ 45,535 $ 49,277 Goodwill Impairment — 5,820 SERP 614 680 Restructuring Expense 10,990 2,386 Asset Impairment (Gain on Disposal) (2,391 ) 17,040 Legal Settlements (Recovery) — (892 ) Stock Compensation Expense 6,519 7,185 Adjusted Operating Income (non-GAAP) $ 61,267 $ 81,496 Tax Effect 24,508 17,297 After-tax Adjusted Operating Income $ 36,759 $ 64,199 Average Invested Capital (1) $ 693,144 $ 782,093 ROIC 5.3 % 8.2 % Expand (1) Average invested capital is computed using Share Owners' equity plus current and non-current debt less cash and cash equivalents averaged for the last five quarters. Expand
